RBC Capital analyst Gerard Cassidy lowered the firm’s price target on Goldman Sachs (GS) to $560 from $610 and keeps a Sector Perform rating on ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $217.00. The ...

Gold prices blasted past $3,500 an ounce for the first time early Tuesday, a record driven by a perfect storm of geopolitical ...

Goldman Sachs analyst Alexander Blostein expects macro and policy uncertainty, volatile equity markets, and declining short-term interest rates to weigh on EPS forecasts for Capital Markets stocks.

Teams at Goldman Sachs, Bank of America, Evercore ISI, RBC Capital Markets, and JPMorgan each see the S&P 500 now ending 2025 ...

Now that earnings season is underway again, investors get a chance to see what's happening behind the scenes of the financial sector, including some of the main players of the United States ...

NEW YORK, April 14 (Reuters) - Goldman Sachs (GS.N), opens new tab beat ... trade norms could hit a slew of firms reliant on capital markets activity. Revenue from Goldman's asset and wealth ...

Goldman Sachs reported a 15% rise in first-quarter ... upend global trade norms could hit a slew of firms reliant on capital markets activity. Revenue at Goldman's asset and wealth management ...

Daiwa Capital Markets downgraded shares of The Goldman Sachs Group (NYSE:GS – Free Report) from an outperform rating to a neutral rating in a research report sent to investors on Friday ...

Goldman Sachs sees macro uncertainty, rate cuts, and weak equity markets pressuring Capital Markets EPS forecasts. Alternative Managers face EPS risks, while Exchanges remain resilient ...

Goldman Sachs analyst Alexander Blostein expects macro and policy uncertainty, volatile equity markets, and declining short-term interest rates to weigh on EPS forecasts for Capital Markets stocks.